This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Latest industry news
    Industry news
    19/02/15

    WHO calls for action on neglected tropical diseases

    19 February 2015 – Seventeen neglected tropical diseases, such as dengue, leprosy or dracunculiasis (guinea-worm disease), currently affect low and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    07/02/25

    MHRA Approves Valneva's Vaccine - Medthority

    MHRA UK approves Valneva's Ixchiq, a new vaccine for chikungunya, marking a significant medical advancement.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/08/17

    KAF 156 + lumefantrine trial launched in Mali to treat malaria.- Novartis

    Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF 156, a next-generation antimalarial compound with...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    05/03/25

    First Child Receives Arpraziquantel

    Preschool-aged child treated with arpraziquantel for schistosomiasis.

    Journals
    Journal
    07/10/16

    Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

    Background: Non-fatal outcomes of disease and injury increasingly detract from the ability of the world's population to live in full health, a trend largely attributable to an epidemiological transition in many countries from causes affecting children, to non-communicable diseases (NCDs) more common in adults.

    • Source: The Lancet
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    10/03/25

    UK MHRA Reviews Chikungunya Vaccine

    Bavarian Nordic's chikungunya vaccine application accepted by UK MHRA, potentially expanding protection to individuals aged 12 and older. Approval expected in 2025.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/02/23

    Bavarian Nordic to acquire portfolio of travel vaccines from Emergent BioSolutions.

    Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and Vaxchora against cholera as well as a Phase III vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to $ 380 million, including $ 270 million in an upfront payment and up to $ 110 million in future conditional milestone payments

    Guidelines
    Guideline
    08/06/23

    ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    ECTRIMS and EAN release a European consensus on vaccination strategies for people with multiple sclerosis. These recommendations aim to optimize immunization before and during treatment with highly active immunotherapeutic drugs.

    • Source: European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / European Academy of Neurology (EAN)
    Journals
    Journal
    30/09/18

    In pursuit of control and elimination: update on hepatitis A and B epidemiology and prevention strategies.

    Purpose of review: This review describes the impact of recommendations for routine immunization of infants and children against hepatitis A and hepatitis B, the changing epidemiology of these infections, and the remaining challenges to controlling or eliminating these diseases in the United States.

    • Source: Current Opinion in Pediatrics
    Guidelines
    Guideline
    20/10/21

    Management of transthyretin amyloidosis: Guidelines from the 1st Swiss Amyloidosis Network (SAN) Consensus conference

    ATTR amyloidosis is a progressive disease caused by transthyretin fibril deposition, leading to organ dysfunction. These SAN guidelines offer consensus-based recommendations for diagnosis and treatment, tailored to the Swiss healthcare system.

    See more